Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Emerging tools in the changing landscape of chronic hepatitis B management.

Gill US, Battisti A, Kennedy PTF.

Expert Rev Anti Infect Ther. 2019 Nov 27:1-13. doi: 10.1080/14787210.2019.1694906. [Epub ahead of print]

PMID:
31738607
2.

Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming.

Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V, Andreata F, Zordan P, Bono E, Giustini L, Bonilla WV, Bleriot C, Kunasegaran K, Gonzalez-Aseguinolaza G, Pinschewer DD, Kennedy PTF, Naldini L, Kuka M, Ginhoux F, Cantore A, Bertoletti A, Ostuni R, Guidotti LG, Iannacone M.

Nature. 2019 Oct;574(7777):200-205. doi: 10.1038/s41586-019-1620-6. Epub 2019 Oct 2.

PMID:
31582858
3.

Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.

Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N, Lampertico P, Fletcher SP, Kennedy PTF, Bertoletti A.

J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30424-6. doi: 10.1016/j.jhep.2019.07.015. [Epub ahead of print]

PMID:
31348999
4.

HBV antiviral immunity: not all CD8 T cells are born equal.

Bertoletti A, Kennedy PTF.

Gut. 2019 May;68(5):770-773. doi: 10.1136/gutjnl-2018-317959. Epub 2019 Jan 30. No abstract available.

PMID:
30700541
5.

Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.

Khakpoor A, Ni Y, Chen A, Ho ZZ, Oei V, Yang N, Giri R, Chow JX, Tan AT, Kennedy PT, Maini M, Urban S, Bertoletti A.

J Virol. 2019 Feb 5;93(4). pii: e01457-18. doi: 10.1128/JVI.01457-18. Print 2019 Feb 15.

6.

Fine needle aspirates comprehensively sample intrahepatic immunity.

Gill US, Pallett LJ, Thomas N, Burton AR, Patel AA, Yona S, Kennedy PTF, Maini MK.

Gut. 2019 Aug;68(8):1493-1503. doi: 10.1136/gutjnl-2018-317071. Epub 2018 Nov 28.

7.

The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics.

Gill US, Kennedy PTF.

J Viral Hepat. 2019 Jan;26(1):4-15. doi: 10.1111/jvh.13040. Epub 2018 Dec 11. Review.

PMID:
30415490
8.

Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.

Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK.

Mol Ther. 2018 Nov 7;26(11):2553-2566. doi: 10.1016/j.ymthe.2018.08.013. Epub 2018 Aug 16.

9.

Circulating and intrahepatic antiviral B cells are defective in hepatitis B.

Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK.

J Clin Invest. 2018 Oct 1;128(10):4588-4603. doi: 10.1172/JCI121960. Epub 2018 Aug 9.

10.

PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.

Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A.

J Clin Invest. 2018 Oct 1;128(10):4573-4587. doi: 10.1172/JCI121957. Epub 2018 Aug 7.

11.

A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B.

Chan HLY, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy PT, Thompson A, Caputo A, Bakalos G, Pavlovic V, Lampertico P.

Aliment Pharmacol Ther. 2018 Sep;48(5):547-555. doi: 10.1111/apt.14862. Epub 2018 Jun 29.

PMID:
29956827
12.

A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia.

Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A, Gadaleta E, Rhys HI, Kennedy PT, Hermida MA, Chang TY, Shaw PE, Reynolds LE, McKay TR, Wang HW, Ribeiro PS, Plevin MJ, Lagos D, Lemoine NR, Rajan P, Graham TA, Chelala C, Hodivala-Dilke KM, Spendlove I, Sharp TV.

EMBO Mol Med. 2018 Aug;10(8). pii: e8304. doi: 10.15252/emmm.201708304.

13.

Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians.

Koffas A, Dolman GE, Kennedy PT.

Clin Med (Lond). 2018 Jun;18(3):212-218. doi: 10.7861/clinmedicine.18-3-212. Review.

14.

Why, who and when to start treatment for chronic hepatitis B infection.

Dolman GE, Koffas A, Mason WS, Kennedy PT.

Curr Opin Virol. 2018 Jun;30:39-47. doi: 10.1016/j.coviro.2018.03.006. Epub 2018 Apr 11. Review.

PMID:
29655092
15.

Liver sampling: a vital window into HBV pathogenesis on the path to functional cure.

Gill US, Pallett LJ, Kennedy PTF, Maini MK.

Gut. 2018 Apr;67(4):767-775. doi: 10.1136/gutjnl-2017-314873. Epub 2018 Jan 13. Review.

16.

Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.

Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, Becht E, Hansi NK, Foster GR, Su TH, Tseng TC, Lim SG, Kao JH, Newell EW, Kennedy PT, Bertoletti A.

J Clin Invest. 2018 Feb 1;128(2):668-681. doi: 10.1172/JCI92812. Epub 2018 Jan 8.

17.

HBV infection and HCC: the 'dangerous liaisons'.

Bertoletti A, Kennedy PTF, Durantel D.

Gut. 2018 May;67(5):787-788. doi: 10.1136/gutjnl-2017-315528. Epub 2017 Dec 1. No abstract available.

PMID:
29196438
18.

TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.

Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF, Oben J, Pinzani M, Walczak H, Fusai G, Rosenberg WMC, Maini MK.

Sci Rep. 2017 Jul 17;7(1):5514. doi: 10.1038/s41598-017-05845-5.

19.

Current therapeutic approaches for HBV infected patients.

Gill US, Kennedy PTF.

J Hepatol. 2017 Aug;67(2):412-414. doi: 10.1016/j.jhep.2017.04.015. Epub 2017 Jun 17. No abstract available.

PMID:
28629790
20.

IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection.

Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, Burton AR, Stegmann KA, Schurich A, Swadling L, Gill US, Male V, Luong T, Gander A, Davidson BR, Kennedy PTF, Maini MK.

J Exp Med. 2017 Jun 5;214(6):1567-1580. doi: 10.1084/jem.20162115. Epub 2017 May 19.

21.

Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks.

Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS.

Viruses. 2017 Apr 29;9(5). pii: E96. doi: 10.3390/v9050096. Review.

22.

Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0.

Salpini R, Piermatteo L, Gill U, Battisti A, Stazi F, Guenci T, Giannella S, Serafini V, Kennedy PTF, Perno CF, Svicher V, Ciotti M.

Med Microbiol Immunol. 2017 Aug;206(4):295-299. doi: 10.1007/s00430-017-0504-3. Epub 2017 Apr 11.

PMID:
28401351
23.

Reply.

Kennedy PTF, Bertoletti A, Mason WS.

Gastroenterology. 2017 Apr;152(5):1246-1247. doi: 10.1053/j.gastro.2017.03.002. Epub 2017 Mar 6. No abstract available.

PMID:
28273438
24.

T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System.

Huang WC, Easom NJ, Tang XZ, Gill US, Singh H, Robertson F, Chang C, Trowsdale J, Davidson BR, Rosenberg WM, Fusai G, Toubert A, Kennedy PT, Peppa D, Maini MK.

J Immunol. 2017 Feb 1;198(3):1172-1182. doi: 10.4049/jimmunol.1601313. Epub 2016 Dec 28.

25.

Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo.

Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PT.

PLoS Pathog. 2016 Aug 3;12(8):e1005788. doi: 10.1371/journal.ppat.1005788. eCollection 2016 Aug.

26.

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.

Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, Hong ML, Naik S, Quaglia A, Bertoletti A, Kennedy PT.

Gastroenterology. 2016 Nov;151(5):986-998.e4. doi: 10.1053/j.gastro.2016.07.012. Epub 2016 Jul 22.

PMID:
27453547
27.

Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host.

Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, Gill US, Hansi N, Kennedy PT, Nastouli E, Gilson R, Frezza C, Henson SM, Maini MK.

Cell Rep. 2016 Aug 2;16(5):1243-1252. doi: 10.1016/j.celrep.2016.06.078. Epub 2016 Jul 21.

28.

Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells.

Pallett LJ, Gill US, Quaglia A, Sinclair LV, Jover-Cobos M, Schurich A, Singh KP, Thomas N, Das A, Chen A, Fusai G, Bertoletti A, Cantrell DA, Kennedy PT, Davies NA, Haniffa M, Maini MK.

Nat Med. 2015 Jun;21(6):591-600. doi: 10.1038/nm.3856. Epub 2015 May 11.

29.

New insights in the management of chronic hepatitis B.

Gill US, Kennedy PT.

Clin Med (Lond). 2015 Apr;15(2):191-6. doi: 10.7861/clinmedicine.15-2-191.

30.

Re: Double coaxial microcatheter technique for transarterial aneurysm sac embolization of type II endoleaks after endovascular abdominal aortic repair.

Conroy DM, Collins AJ, Kennedy PT.

J Vasc Interv Radiol. 2014 Nov;25(11):1827-8. doi: 10.1016/j.jvir.2014.07.028. Epub 2014 Oct 23. No abstract available.

PMID:
25442144
31.

The immune tolerant phase of chronic HBV infection: new perspectives on an old concept.

Bertoletti A, Kennedy PT.

Cell Mol Immunol. 2015 May;12(3):258-63. doi: 10.1038/cmi.2014.79. Epub 2014 Sep 1. Review.

32.

Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?

Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, Kallis YN, Marley RT, Kooner P, Foster GR, Kennedy PT.

J Infect Dis. 2015 Feb 1;211(3):374-82. doi: 10.1093/infdis/jiu471. Epub 2014 Aug 25.

PMID:
25156561
33.

Chronic hepatitis B virus in young adults: the need for new approaches to management.

Gill US, Kennedy PT.

Expert Rev Anti Infect Ther. 2014 Sep;12(9):1045-53. doi: 10.1586/14787210.2014.940899. Epub 2014 Jul 23. Review.

PMID:
25052517
34.

Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver.

Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A, To N, Hong M, Chia A, Gill US, Kennedy PT, Tan KC, Lee KH, De Libero G, Gehring AJ, Willberg CB, Klenerman P, Bertoletti A.

PLoS Pathog. 2014 Jun 26;10(6):e1004210. doi: 10.1371/journal.ppat.1004210. eCollection 2014 Jun.

35.

Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A, Banu N, Chia A, Lim SG, Ferrari C, Ginhoux F, Bertoletti A.

J Clin Invest. 2013 Sep;123(9):3766-76. doi: 10.1172/JCI66043. Epub 2013 Aug 1.

36.

The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells.

Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK.

PLoS Pathog. 2013 Mar;9(3):e1003208. doi: 10.1371/journal.ppat.1003208. Epub 2013 Mar 14.

37.

Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion.

Peppa D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, Kennedy PT, Maini MK.

J Exp Med. 2013 Jan 14;210(1):99-114. doi: 10.1084/jem.20121172. Epub 2012 Dec 17.

38.

IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection.

Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P, Dusheiko G, Gill U, Kennedy PT, Brunetto M, Lampertico P, Mauri C, Maini MK.

J Immunol. 2012 Oct 15;189(8):3925-35. doi: 10.4049/jimmunol.1103139. Epub 2012 Sep 12.

39.

Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.

Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR, Bertoletti A.

Gastroenterology. 2012 Sep;143(3):637-645. doi: 10.1053/j.gastro.2012.06.009. Epub 2012 Jun 15.

PMID:
22710188
40.

IL-2-engineered nano-APC effectively activates viral antigen-mediated T cell responses from chronic hepatitis B virus-infected patients.

Liu M, Miao T, Zhu H, Symonds AL, Li L, Schurich A, Maini MK, Zhang J, Kennedy PT, Li S, Wang P.

J Immunol. 2012 Feb 1;188(3):1534-43. doi: 10.4049/jimmunol.1102709. Epub 2011 Dec 30.

41.

Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection.

Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, Nebbia G, Kennedy PT, Geretti AM, Dusheiko G, Maini MK.

Hepatology. 2011 May;53(5):1494-503. doi: 10.1002/hep.24249.

PMID:
21360567
42.

Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection.

Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK.

PLoS Pathog. 2010 Dec 16;6(12):e1001227. doi: 10.1371/journal.ppat.1001227.

43.

Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody.

Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L, Kennedy PT, Lopatin U, Macary PA, Bertoletti A.

J Virol. 2011 Mar;85(5):1935-42. doi: 10.1128/JVI.01990-10. Epub 2010 Dec 15.

44.

The safety and utility of prophylactic pancreatic duct stents in the prevention of post-ERCP pancreatitis: an analysis of practice in a single UK tertiary referral center.

Kennedy PT, Russo E, Kumar N, Powell N, Bansi D, Thillainayagam A, Vlavianos P, Westaby D.

Surg Endosc. 2010 Aug;24(8):1923-8. doi: 10.1007/s00464-009-0875-7. Epub 2010 Jan 29.

PMID:
20112114
45.

The pea, the yeast and the prostate.

Pasha Y, Blunt D, Kennedy PT.

QJM. 2010 Apr;103(4):265-6. doi: 10.1093/qjmed/hcp160. Epub 2009 Nov 10. No abstract available.

PMID:
19903726
46.

NICE guidelines and a treatment algorithm for the management of chronic hepatitis B: a review of 12 years experience in west London.

Kennedy PT, Lee HC, Jeyalingam L, Malik R, Karayiannis P, Muir D, Main J, Thursz M, Goldin R, Smith B, Brown A, Thomas HC.

Antivir Ther. 2008;13(8):1067-76.

PMID:
19195332
47.

The expression and function of NKG2D molecule on intrahepatic CD8+ T cells in chronic viral hepatitis.

Kennedy PT, Gehring AJ, Nowbath A, Selden C, Quaglia A, Dhillon A, Dusheiko G, Bertoletti A.

J Viral Hepat. 2008 Dec;15(12):901-9. doi: 10.1111/j.1365-2893.2008.01049.x.

PMID:
19087227
48.

Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection.

Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT, Alexander G, Finney H, Lawson A, Plunkett FJ, Bertoletti A, Akbar AN, Maini MK.

J Exp Med. 2008 Sep 1;205(9):2111-24. doi: 10.1084/jem.20072076. Epub 2008 Aug 11.

49.

Failed retrieval of an inferior vena cava filter during pregnancy because of filter tilt: report of two cases.

McConville RM, Kennedy PT, Collins AJ, Ellis PK.

Cardiovasc Intervent Radiol. 2009 Jan;32(1):174-7. doi: 10.1007/s00270-008-9393-6. Epub 2008 Aug 2.

PMID:
18677532
50.

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.

Kennedy PT, Phillips N, Chandrasekhar J, Jacobs R, Jacobs M, Dusheiko G.

Liver Int. 2008 May;28(5):699-704. doi: 10.1111/j.1478-3231.2008.01717.x.

PMID:
18433396

Supplemental Content

Loading ...
Support Center